Rilonacept

From Wikipedia, the free encyclopedia

Rilonacept
Systematic (IUPAC) name
n/a
Identifiers
CAS number  ?
ATC code L04AC04
PubChem  ?
Chemical data
Formula  ?
Mol. mass  ?
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Licence data

US
Pregnancy cat.

C(US)
Legal status

℞-only(US)
Routes Subcutaneous

Rilonacept (marketed under the tradename Arcalyst), is a dimeric fusion protein for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS). It was given an "Orphan Drug" status by the United States Food and Drug Administration.

It was approved by the FDA on February 2008.[1]

[edit] References

  1. ^ Drugs.com, FDA Approves Arcalyst - New Orphan Drug for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS). Retrieved on 2008-03-15.

[edit] External links

v • d • e
Immunomodulators - Immunosuppressants - Immunosuppressive drugs (L04)
Monoclonal antibodies
TNF inhibitors (Infliximab, Adalimumab, Certolizumab pegol), Afelimomab, Aselizumab, Atlizumab, Atorolimumab, Basiliximab, Belimumab, Bertilimumab, Cedelizumab, Clenoliximab, Daclizumab, Dorlimomab aritox, Dorlixizumab, Eculizumab, Efalizumab, Elsilimomab, Erlizumab, Faralimomab, Fontolizumab, Galiximab, Gantenerumab, Gavilimomab, Golimumab, Gomiliximab, Ibalizumab, Inolimomab, Ipilimumab, Keliximab, Lebrilizumab, Lerdelimumab, Lumiliximab, Maslimomab, Mepolizumab, Metelimumab, Morolimumab, Muromonab-CD3, Natalizumab, Nerelimomab, Ocrelizumab, Odulimomab, Omalizumab, Otelixizumab, Pascolizumab, Pexelizumab, Reslizumab, Rovelizumab, Ruplizumab, Siplizumab, Talizumab, Telimomab aritox, Teneliximab, Teplizumab, Tocilizumab, Toralizumab, Vapaliximab, Vepalimomab, Visilizumab, Zanolimumab, Ziralimumab, Zolimomab aritox
-imus
-cept (Fusion protein)
Other
Pills  This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.